BACKGROUND: The role of consolidation radiotherapy was examined for @entity1 with diffuse large @entity1892 who were treated at institutions of the National @entity5 Network during the rituximab era. METHODS: @entity177 ( @entity177 ) and @entity1349 ( @entity1349 ) were analyzed in terms of @entity1 and treatment characteristics. Potential associations were investigated with univariate and multivariate survival analysis and matched pair analysis. RESULTS: There were 841 @entity1 , and most (710 or 84%) received 6 to 8 cycles of rituximab, @entity786 , @entity632 , @entity1891 , and @entity229 (R- @entity3726 ); 293 (35%) received consolidation @entity1161 ( @entity1161 ). Failure occurred for 181 @entity1 : 126 @entity1 (70%) who did not receive @entity1161 and 55 @entity1 (30%) who did. At 5 years, both @entity1349 and @entity177 rates were better for @entity1 who had received @entity1161 versus those who did not ( @entity1349 , 91% vs 83% [P   =   .01]; @entity177 , 83% vs 76% [P   =   .05]). A matched pair analysis (217 pairs matched by age, stage, International Prognostic Index [IPI] score, B symptoms, disease bulk, and response to chemotherapy) showed that the receipt of @entity1161 improved @entity1349 (hazard ratio [HR], 0.53 [P   =   .07]) and @entity177 (HR, 0.77 [P   =   .34]) for @entity1 with @entity5 , but too few events took place among those with stage I/II disease for meaningful comparisons (HR for @entity1349 , 0.94 [P   =   .89]; HR for @entity177 , 1.81 [P   =   .15]). A multivariate analysis suggested that the IPI score and the response to chemotherapy had the greatest influence on outcomes. CONCLUSIONS: There was a trend of higher @entity1349 and @entity177 rates for @entity1 who had received consolidation @entity1161 after R- @entity3726 (especially for @entity1 with @entity5 ), but the difference did not reach statistical significance. @entity5 2014.    2014 American @entity5 Society.

Radiation for diffuse large XXXX in the rituximab era: Analysis of the National @entity5 outcomes project.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III/IV disease', 'Comprehensive Cancer', 'Cancer'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity3726 :: ('1649', 'Gene') :: ['CHOP'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity177 :: ('MESH:D051437', 'Disease') :: ['FFS', 'Failure-free survival'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphoma']
